Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities

Man Wang, Yanqiu Zhao, Ke Xu, Chao Liu, Hui Zhong, You Wu, Ke Zhang, Shi WeiFrontiers in Immunology 2025 · DOI

TL;DR

This review identifies cancer-associated fibroblasts (CAFs) as the primary architects of the immunosuppressive "neighborhood" in clear cell renal cell carcinoma (ccRCC). By reshaping the physical environment and signaling to immune cells, CAFs drive a vicious cycle of therapy resistance, making them a critical—but highly complex—target for the next generation of precision cancer treatments.

What Problem Does This Paper Address?

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive form of kidney cancer. While targeted therapies (like VEGF inhibitors) and immunotherapies have improved patient outcomes, many patients eventually develop resistance.

The authors argue that we have spent too much time looking at the "seeds" (the cancer cells) and not enough at the "soil" (the tumor microenvironment, or TME). Within this soil, CAFs are pivotal. However, CAFs aren't a single cell type; they are a diverse, "heterogeneous" population with various origins and functions. This paper synthesizes current research to map out how these different CAF subtypes interact with the immune system and why they make ccRCC so difficult to treat.

Methods

As a Mini Review, this paper does not present new experimental data. Instead, the authors performed a systematic synthesis of existing literature, clinical trial data (from ClinicalTrials.gov), and recent breakthroughs in single-cell RNA sequencing (scRNA-seq). They specifically analyzed the "multidimensional regulatory network" of CAFs, categorizing them by their cellular origins, functional subtypes (like myofibroblastic vs. inflammatory CAFs), and their molecular crosstalk with other cells in the TME.

Datasets

The paper synthesizes findings from several key sources rather than training a model on a specific dataset:

  • Clinical Trial Registries: Data from ClinicalTrials.gov was used to compile Table 1 (biomarker applications) and Table 2 (major ICI combination trials like CheckMate 214, KEYNOTE-426, and CLEAR).
  • Single-Cell Repositories: The authors reference specific scRNA-seq studies (e.g., Kieffer et al., 2020) that have identified distinct CAF subpopulations (FAP+ CAFs) in solid tumors.
  • Literature Review: A comprehensive survey of 102 cited papers covering the molecular biology and clinical landscape of ccRCC.

Key Insights and Ideas

  • The "Vicious Cycle" of Resistance: CAFs don't just sit there; they actively recruit and "reprogram" immune cells. They drive monocytes to become immunosuppressive M2 macrophages and expand regulatory T cells (Tregs), which in turn protect the tumor from the patient's own immune system.
  • Mechanical Exclusion: CAFs are the primary builders of the Extracellular Matrix (ECM). In ccRCC, they stiffen the ECM, creating a physical "fortress" that prevents cytotoxic T lymphocytes (the "killer" cells) from reaching the tumor core.
  • Metabolic Feeding: CAFs undergo metabolic reprogramming (glycolysis) to produce energy substrates that they essentially "hand over" to cancer cells, fueling tumor growth even in nutrient-poor environments.
  • Functional Dichotomy: The review highlights the discovery of two main subtypes: myCAFs (myofibroblastic), which focus on ECM remodeling and TGF-β signaling, and iCAFs (inflammatory), which secrete pro-inflammatory cytokines like IL-6 and CXCL8 to amplify immune evasion.
  • Exosomal "Care Packages": CAFs secrete exosomes containing non-coding RNAs (like miR-590-3p) that are swallowed by cancer cells, directly triggering pathways that inhibit cell death and promote resistance to radiation and chemotherapy.

Key Results

The authors highlight that while combination therapies—specifically Immune Checkpoint Inhibitors (ICIs) paired with VEGF antagonists—are the current gold standard, their efficacy is often blunted by CAF activity.

  • Synergy: IL-6 from CAFs synergizes with VEGF to drive adaptive resistance.
  • Targeting FAP: Early-stage trials and preclinical models using CAR-T cells targeted at Fibroblast Activation Protein (FAP) show promise in "breaking" the CAF-mediated barrier.
  • Clinical Trials: The review notes that trials like CheckMate 214 show significantly better survival with combination therapy (Nivolumab + Ipilimumab) compared to older monotherapies, but CAF-rich tumors remain the "hardest nuts to crack."

Limitations and Future Work

The biggest hurdle identified is CAF heterogeneity. Because CAFs can have "dual roles"—sometimes even restraining tumor growth in specific contexts—simply killing all fibroblasts (total ablation) can backfire and lead to even more aggressive disease.

Future Directions: 1. Spatial Multi-omics: We need to know not just what these cells are, but where they are located in relation to the tumor and immune cells. 2. Precision Subtyping: Developing specific biomarkers to identify which CAF subtype is dominant in a patient, allowing for "precision reprogramming" rather than blunt destruction. 3. Breaking the Cycle: Moving beyond targeting the tumor cells alone to therapies that "normalize" the CAF behavior, essentially turning a hostile neighborhood back into a healthy one.

Summary updated

Abstract

Clear cell renal cell carcinoma (ccRCC) progression heavily relies on the immunosuppressive tumor microenvironment (TME). In the ccRCC TME, the cancer-associated fibroblasts (CAFs) drive a self-perpetuating cycle of immune evasion and therapeutic resistance through diverse interactions between cells and molecules. Furthermore, heterogeneous CAFs facilitate tumor growth through metabolic reprogramming and modulate immune suppression by driving the M2 polarization of tumor-associated macrophages (TAMs) and the expansion of regulatory T cells (Tregs), which promote a multilayered immunosuppressive network. In addition, CAFs reshape the mechanical properties of extracellular matrix (ECM), hinder the infiltration of cytotoxic T lymphocytes (CTLs) and further exacerbate immune escape. Moreover, CAF-derived exosomes can confer resistance to chemoradiation therapy. Interleukin-6 (IL-6) secreted by CAFs synergizes with vascular endothelial growth factor (VEGF) to facilitate adaptive resistance to targeted therapy. Emerging therapeutic strategies-including fibroblast activation protein (FAP)-targeted CAR-T cells and transforming growth factor-β (TGF-β) inhibitors-can partially reverse this immunosuppressive property. Combination therapies employing immune checkpoint inhibitors and VEGF antagonists exhibit promising synergistic effects, although the clinical translation remains hampered by CAF heterogeneity, dual functional roles, and the lack of specific biomarkers. Future studies should integrate single-cell sequencing and spatial multi-omics techniques to comprehensively analyze the spatio-temporal dynamic heterogeneity of CAF subpopulations and develop precision treatment strategies based on molecular subtyping, aiming to break the vicious cycle of "CAF-TME-resistance" in ccRCC.
BibTeX
@inproceedings{wang2025cancer,
  author = {Man Wang and Yanqiu Zhao and Ke Xu and Chao Liu and Hui Zhong and You Wu and Ke Zhang and Shi Wei},
  title = {{Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1617968},
}
Figure